# Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)

> **NCT04949009** · — · UNKNOWN · sponsor: **Shandong University** · enrollment: 400 (estimated)

## Conditions studied

- Primary Immune Thrombocytopenia

## Interventions

- **DRUG:** Avatrombopag

## Key facts

- **NCT ID:** NCT04949009
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2021-10-01
- **Final completion:** 2022-03
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2021-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04949009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04949009, "Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04949009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*